Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
One of the diuretic which is planned to be used in the study is no longer available.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Add furosemide/no spironolactone | Experimental |
| |
| Add metolazone/no spironolactone | Experimental |
| |
| Add furosemid/spironolactone | Experimental |
| |
| Add metolazone/spironolactone | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Furosemide | Drug | furosemide (doubling previous furosemide dose) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| urine output change | efficacy of diuretics add-on therapy, urine output change | from admission to Hospital Day (HOD)#4 |
| Measure | Description | Time Frame |
|---|---|---|
| serum creatinine change | safety of diuretics add-on therapy, serum creatinine change | from admission to HOD#4 |
| Measure | Description | Time Frame |
|---|---|---|
| body weight change | body weight change, symptoms & signs change | from admission to HOD#4 |
| urine creatinine change | urine creatinine change, serum & urine electrolyte change, biomarkers change |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| metolazone |
| Drug |
metolazone (add 2.5mg qod) |
|
| furosemid/spironolactone | Drug | spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user) |
|
| metolazone/spironolactone | Drug | no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user) |
|
| from admission to HOD#4 |
| clinical outcomes | clinical outcomes ( all-cause mortality, all-cause rehospitalization, start of renal replacement therapy) | at 90 days after discharge |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005665 | Furosemide |
| D008788 | Metolazone |
| D013148 | Spironolactone |
| ID | Term |
|---|---|
| D013424 | Sulfanilamides |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D052999 | Quinazolinones |
| D011799 | Quinazolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D007783 | Lactones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided